Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.

Abstract

AIM:

The main aim of this study was to determine whether questionnaire evaluations of clinical symptoms in gastroesophageal reflux disease were useful to assess proton pump inhibitor therapy.

METHODS:

A total of 185 Japanese patients (men, 88; women, 97; age: 55.7 ± 16.1 years) with gastroesophageal reflux disease were enrolled. The patients were divided based on the frequency scale for symptoms of gastroesophageal reflux disease: severe symptoms with scores ≥8 and mild symptoms with scores ≤7. Quality of life was evaluated with the Medical Outcomes Study 8-Item Short-Form Health Survey. All patients were treated with a proton pump inhibitor, rabeprazole (10 mg/day), for 8 weeks.

RESULTS:

Patients were classified into four groups: reflux esophagitis with severe symptoms (n = 92, 49.7%); reflux esophagitis with mild symptoms (n = 17, 9.2%); non-erosive reflux disease with severe symptoms (n = 66, 35.7%); and non-erosive reflux disease with mild symptoms (n = 10, 5.4%). The dysmotility score was high in non-erosive reflux disease with severe symptoms compared with reflux esophagitis with severe symptoms (9.1 ± 0.5 vs 6.8 ± 0.5, P < 0.05). The symptom score and quality of life in the severe symptoms groups for both reflux esophagitis and non-erosive reflux disease were significantly improved by rabeprazole treatment. Only the reflux score was improved by rabeprazole in the reflux esophagitis with mild symptoms group; no therapeutic effect was observed for the non-erosive reflux disease with mild symptoms group.

CONCLUSIONS:

Low scores on the frequency scale for the symptoms of gastroesophageal reflux disease indicate poor responsiveness to proton pump inhibitor treatment, and high scores indicate good responsiveness.

• Authors: Mio Komatsu-Tanaka, Ryuichi Iwakiri, Kazuma Fujimoto, Yasuhiro Fujiwara, Masahiko Inamori, Junji Tanaka, Tomohiko Shimatani, Junichi Akiyama, Takashi Ando, Noriaki Manabe, Fukunori Kinjo, Ryuzo Deguchi, Motoyasu Kusano
• Journal: Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society (Dig Endosc) Vol. 24 Issue 6 Pg. 407-11 (Nov 2012) ISSN: 1443-1661 [Electronic] Australia
• PMID: 23078431 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: © 2012 The Authors. Digestive Endoscopy © 2012 Japan Gastroenterological Endoscopy Society.

Chemical References

• 2-Pyridinylmethylsulfinylbenzimidazoles
• Anti-Ulcer Agents
• Proton Pump Inhibitors
• Rabeprazole
• Proton-Translocating ATPases

Topics

• 2-Pyridinylmethylsulfinylbenzimidazoles (therapeutic use)
• Aged
• Anti-Ulcer Agents (therapeutic use)
• Female
• Gastroesophageal Reflux (diagnosis, drug therapy, epidemiology)
• Humans
• Japan (epidemiology)
• Male
• Middle Aged
• Prevalence
• Proton Pump Inhibitors (therapeutic use)
• Proton-Translocating ATPases (antagonists & inhibitors)
• Quality of Life
• Rabeprazole
• Retrospective Studies
• Severity of Illness Index
• Surveys and Questionnaires
• Treatment Outcome